PMID- 34484389
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - Efficacy and Safety of Curcumin Supplement on Improvement of Insulin Resistance 
      in People with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 
      Randomized Controlled Trials.
PG  - 4471944
LID - 10.1155/2021/4471944 [doi]
LID - 4471944
AB  - BACKGROUND: Diabetes is a major public health concern. In addition, there is some 
      evidence to support curcumin as part of a diabetes treatment program. METHODS: 
      Data from randomized controlled trials were obtained to assess the effects of 
      curcumin versus placebo or western medicine in patients with type 2 diabetes 
      mellitus (T2DM). The study's registration number is CRD42018089528. The primary 
      outcomes included homeostasis model assessment-insulin resistance (HOMA-IR), 
      glycosylated hemoglobin (HbAlc), total cholesterol (TC), and triglyceride (TG). 
      RESULTS: Four trials involving 453 patients were included. The HOMA-IR of 
      curcumin group is lower in Asia (WMD: -2.41, 95% CI: -4.44 to -0.39, P=0.02) and 
      the Middle East subgroups (WMD: -0.60, 95% CI: -0.74 to -0.46, P < 0.00001). The 
      HbAlc in the curcumin group is lower than that in the control group (WMD: -0.69; 
      95% CI: -0.91, -0.48; P < 0.0001). The TC and TG levels of the curcumin group are 
      lower in the Asia subgroup (TC: WMD: -23.45, 95% CI: -40.04 to -6.84, P=0.006; 
      TG: WMD: -54.14, 95% CI: -95.71 to -12.57, P=0.01), while in the Middle East the 
      difference was of not statistically significant (TC: WMD: 22.91, 95% CI: -16.94 
      to 62.75, P=0.26; TG: WMD: -4.56, 95% CI: -19.28 to 10.16, P=0.54). CONCLUSION: 
      Based on the current evidence, curcumin may assist in improving the insulin 
      resistance, glycemic control, and decreased TG and TC in patients with T2DM.
CI  - Copyright (c) 2021 Tianqing Zhang et al.
FAU - Zhang, Tianqing
AU  - Zhang T
AD  - The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang 
      Medical School, University of South China, Hengyang, Hunan Province, China.
FAU - He, Qi
AU  - He Q
AUID- ORCID: 0000-0002-3243-8002
AD  - People's Hospital of Ningxiang City, Ningxiang City, Hunan Province, China.
FAU - Liu, Yao
AU  - Liu Y
AD  - The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang 
      Medical School, University of South China, Hengyang, Hunan Province, China.
FAU - Chen, Zhenrong
AU  - Chen Z
AD  - The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang 
      Medical School, University of South China, Hengyang, Hunan Province, China.
FAU - Hu, Hengjing
AU  - Hu H
AUID- ORCID: 0000-0002-1187-3611
AD  - The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang 
      Medical School, University of South China, Hengyang, Hunan Province, China.
AD  - Institute of Cardiovascular Disease and Key Lab for Arteriosclerology of Hunan 
      Province, University of South China, Hengyang, Hunan, China.
LA  - eng
PT  - Journal Article
DEP - 20210824
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8410384
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2021/09/07 06:00
MHDA- 2021/09/07 06:01
PMCR- 2021/08/24
CRDT- 2021/09/06 05:57
PHST- 2021/06/06 00:00 [received]
PHST- 2021/07/20 00:00 [accepted]
PHST- 2021/09/06 05:57 [entrez]
PHST- 2021/09/07 06:00 [pubmed]
PHST- 2021/09/07 06:01 [medline]
PHST- 2021/08/24 00:00 [pmc-release]
AID - 10.1155/2021/4471944 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Aug 24;2021:4471944. doi: 
      10.1155/2021/4471944. eCollection 2021.